UCBJY: Summary for UCB UNSP ADR EACH REPR 0.5 ORD - Yahoo Finance

UK Markets closed

UCB SA (UCBJY)


Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
40.17+0.38 (+0.96%)
At close: 3:45PM EDT
People also watch
TKPYYUMICYMKGAYDSNKYESALY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close39.79
Open0.00
Bid0.00 x
Ask0.00 x
Day's range0.00 - 0.00
52-week range
Volume86
Avg. volume1,038
Market cap14.86B
Beta0.34
PE ratio (TTM)27.19
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield0.62 (1.55%)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • UCB SA : UCBJY-US: Dividend Analysis : May 02nd, 2017 (record date) : By the numbers : April 28, 2017
    Capital Cube2 days ago

    UCB SA : UCBJY-US: Dividend Analysis : May 02nd, 2017 (record date) : By the numbers : April 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing UCB SA with the following peers – Amgen Inc., Shire PLC Sponsored ADR, Pfizer Inc., Biogen Inc., Novartis AG Sponsored ADR and Catalyst Pharmaceuticals, Inc. (AMGN-US, SHPG-US, PFE-US, BIIB-US, NVS-US and CPRX-US). UCB SA’s dividend yield is 1.03 percent and its dividend payout is 24.00 ... Read more (Read more...)

  • PR Newswire9 days ago

    UCB showcases latest epilepsy research at 2017 Annual Meeting of the American Academy of Neurology

    Data being presented include posters further describing the efficacy and tolerability profile of VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV. Posters will be presented describing the efficacy and tolerability of lacosamide monotherapy in elderly newly diagnosed epilepsy patients and in newly diagnosed epilepsy patients with psychiatric comorbidities. Pooled results from long-term follow-up studies of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures and a poster comparing the healthcare utilization and direct medical costs in newly diagnosed epilepsy patients compared to a non-epilepsy population will also be presented.

  • PR Newswire19 days ago

    Labor Commissioner Mark Butler Joins Atlanta Businesses at the EFWorks Launch Forum

    ATLANTA, April 11, 2017 /PRNewswire/ -- The Epilepsy Foundation of Georgia (EFGA), with sponsorship from UCB, Inc., a biopharmaceutical company, had the pleasure of hosting Georgia Labor Commissioner Mark Butler and Atlanta-area business at the EFWorks Employer Forum. Attendees included companies large and small.